Status:
RECRUITING
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Lead Sponsor:
University Hospitals, Leicester
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
10-99 years
Brief Summary
Bicuspid aortic valve (BAV) is the most common congenital heart anomaly in the general population (1-2% of all individuals). In affected people, the aortic valve (the structure ensuring one way blood ...
Detailed Description
Bicuspid aortic valve is the most common congenital valvular heart anomaly in the general population, with a prevalence estimated between 0.5 - 2%. It is more common in males than females with ratios ...
Eligibility Criteria
Inclusion
- \- 1. All outpatients and inpatients with diagnosed BAV, of either gender, aged 10 and above.
- 2\. Affected and unaffected first degree relatives meeting the age criteria.
Exclusion
- 1\) Patients unable to give informed consent.
- 2\) Patients known to be infected with HIV, Hepatitis B, Hepatitis C or any other agent posing an infection risk from unfixed material.
- 3\) Patient with known cytogenetic disorders e.g. aneuploidia, chromosomal abnormalities and known karyotype abnormalities.
- 4\) Patients with diagnosed or suspected Mendelian syndromes (e.g. Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome).
Key Trial Info
Start Date :
September 8 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 3 2027
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04514445
Start Date
September 8 2015
End Date
November 3 2027
Last Update
November 29 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Kettering General Hospital
Kettering, United Kingdom
2
University Hospitals of Leicester
Leicester, United Kingdom
3
Imperial College Healthcare NHS Trust
London, United Kingdom
4
Sheffield Teaching Hospital NHS Foundation Trust
Sheffield, United Kingdom